Jan 09

A new drug in the world for multidrug-resistant tuberculosis (MDR-TB)

What is Tuberculosis?

Tuberculosis is one of the deadliest diseases in the world for which a limited number of medicines are available. It is an infection caused by the bacteria Mycobacterium tuberculosis which mainly infects the lungs. This infection can be speeded from person to person through air. Thus it is highly contagious disease.

What is multidrug-resistant tuberculosis (MDR-TB)?

As of today there are only two effective drugs available to treat Tuberculosis – Isoniazid and Rifampin. The patients have to take these drugs for a long period of time regularly. If any patient feels better and quit the drug intake before the antibiotic course schedule then there is a chance that bacteria may be resistant to the treatment. And there are some bacteria which are not responded to these antibiotics. When Tuberculosis is not cured by these two standard drugs, Isoniazid and Rifampin, then it is called multidrug-resistant tuberculosis (MDR-TB).

A new drug for multidrug-resistant tuberculosis (MDR-TB)

Rifampin was the last drug approved for TB in 1970. And after more than 40 years FDA has been recently approved a new drug, Bedaquiline, for the treatment of multidrug-resistant tuberculosis (MDR-TB). It was approved under the FDA’s accelerated approval program. This antibiotic acts by a novel mode of action by inhibition of a mycobacterial enzyme that is essential to the bacteria's action. Bedaquiline has to be used as part of the standard therapy to treat MDR-TB.

Skip to toolbar